ArticleTranslational lung cancer research2025
Clinical implication of tumor spread through air spaces in stage IA lung adenocarcinoma: prognostic impact and association with the International Association for the Study of Lung Cancer (IASLC) grade.
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Spread through air spaces as an independent prognostic factor in resected lung adenocarcinoma: the role of resection type.World journal of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tumor spread through air spaces (STAS) and a new histological grading system proposed by the International Association for the Study of Lung Cancer (IASLC) have been studied for risk stratification and prognostic assessment in patients with lung adenocarcinoma (LUAD). This study aimed to clarify the association between STAS and IASLC grade and to assess the prognostic significance of STAS in patients with pathological stage (p-stage) IA LUAD as stratified by the IASLC grading system. Methods: This study included 789 patients with resected p-stage IA LUAD treated between 2018 and 2020. Logistic regression analysis was performed to assess the association between STAS and clinicopathological characteristics. A Cox proportion hazards model was used to assess the risk factors related to recurrence-free survival (RFS) and overall survival (OS). Results: STAS was present in 242 patients (30.7%). The independent factors associated with the presence of STAS were nodule type [odds ratio (OR) =3.89; 95% confidence interval (CI): 2.69-5.62; P<0.001], IASLC grade (grade 2: OR =12.41, 95% CI: 3.83-40.23; P<0.001; grade 3: OR =27.35, 95% CI: 8.24-90.82, P<0.001), and lymphovascular invasion (OR =3.30; 95% CI: 1.72-6.35; P<0.001). For all patients (N=789), STAS and IASLC grade were independent prognostic factors for RFS and OS. For grade 2 LUAD, p-stage T1c was an independent prognostic factor for RFS [hazard ratio (HR) =4.30, 95% CI: 1.07-19.08; P=0.045] and OS (HR =4.95, 95% CI: 1.14-21.54; P=0.03). STAS was significantly correlated with unfavorable RFS (HR =2.81; 95% CI: 1.32-5.97; P=0.007) and OS (HR =2.04, 95% CI: 1.40-7.75; P=0.006) in patients with grade 3 tumors. Conclusions: The presence of STAS was not only directly correlated with the IASLC grading system, but was also a prognostic factor for worse RFS and OS in grade 3 LUAD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.